All News
Filter News
Found 304 articles
-
Alaunos Therapeutics, Satsuma Pharmaceuticals, NeuroSense, Emyria and more reported updates in solid tumors, migraine, ALS and MDMA drug discovery.
-
Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
9/21/2022
Alaunos Therapeutics, Inc. today announced early clinical data from the first patient in its ongoing TCR-T Library Phase 1/2 trial.
-
Elicio Therapeutics Receives $2.8 Million Grant from the Gastro-Intestinal Research Foundation (GIRF) to Fund Research for Two Therapeutic Cancer Vaccines
9/20/2022
Elicio Therapeutics announced that it has been awarded a $2.8 million grant from the Gastro-Intestinal Research Foundation in Chicago to fund research for two therapeutic cancer vaccines.
-
Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September 2022
9/7/2022
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, announced Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development will be participating in the following upcoming investor conferences.
-
Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy
9/6/2022
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced early clinical findings from its ongoing TCR-T Library Phase 1/2 trial.
-
Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
8/24/2022
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that it has been accepted to present a proffered talk at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (CICON) being held in New York, NY from September 28 – October 1, 2022.
-
Revolution Medicines Reports Second Quarter 2022 Financial Results and Update on Corporate Progress
8/9/2022
Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced its financial results for the quarter ended June 30, 2022, and provided an update on corporate progress.
-
Initial Analysis of Tumor Profiling From a Prospective Study by Foundation Medicine
8/8/2022
Foundation Medicine, Inc., Flatiron Health, and Genentech, members of the Roche Group, in partnership with a network of community oncology practices, today announced new research in the Journal of Thoracic Oncology Clinical and Research Reports.
-
Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022
8/8/2022
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the second quarter ended June 30, 2022 on Monday, August 15, 2022, before the open of U.S. markets.
-
Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations
8/4/2022
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, announced the appointment of Abhishek Srivastava, Ph.D. as Vice President of Technical Operations.
-
Novartis and UC Berkeley Extend Alliance to Tackle 'Undruggable' Disease Targets and Discover New Therapeutic Modalities
7/28/2022
Novartis and the University of California, Berkeley have extended their research-based collaboration to develop new technologies for the discovery of next-generation therapeutics, following its successes over the last five years.
-
HotSpot Therapeutics Appoints Paul Thibodeau, Ph.D., as Chief Business Officer
7/25/2022
HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Paul Thibodeau , Ph.D., as Chief Business Officer.
-
HotSpot Therapeutics Appoints Jose Carmona to Board of Directors
7/19/2022
HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Jose "Pepe" Carmona to its Board of Directors.
-
Personalized Cancer Vaccine Clinical Trials Market Insight
7/5/2022
During last few years, immunotherapy has emerged out to be promising cancer therapy in addition to surgery, chemotherapy and radiotherapy. Immunotherapy has shown a significant therapeutic effect in wide range of human cancer by using the immune system to eliminate cancer cells
-
Cambridge, Massachusetts’ Kendall Square just got a little more crowded following the announcement that life sciences giant Bayer opened its new Research and Innovation Center.
-
Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025
6/27/2022
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company, today announced that the Company has extended its Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) .
-
The new space will enable Astellas to establish a global supply chain of gene therapies as well as widen the scope of the therapeutic products it creates.
-
Junshi Biosciences Highlights Pipeline Advances in Immuno-Oncology Through Nearly 40 Data Presentations of Icatolimab and Toripalimab at ASCO 2022
6/7/2022
Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that the company highlighted its pipeline advances in immunotherapy drugs, including anti-PD-1 monoclonal antibody toripalimab and anti-BTLA monoclonal antibody icatolimab (TAB004/JS004).
-
Alaunos Therapeutics to Present at the Jefferies Healthcare Conference - June 01, 2022
6/1/2022
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company announced that Kevin S. Boyle Sr., Chief Executive Officer and Drew Deniger, Ph.D., Vice President, Research & Development will present at the upcoming Jefferies Healthcare Conference being held on June 8-10, 2022, in New York, NY.
-
Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting
5/26/2022
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), a clinical-stage oncology-focused cell therapy company today announced a Trials in Progress poster presentation at the 2022 American Society of Clinical Oncology Annual Meeting being held in Chicago, IL June 3-7, 2022.